Citation

Švestka J. Psychiatr. 2014; 18(2): 98-105.

Copyright

(Copyright © 2014, Tigis S R O)

DOI

unavailable

PMID

unavailable

Abstract

There are 22 antidepressants registered for the treatment of depressive disorder in the Czech Republic. Currently 22 new compounds with antidepressant acitivity are being developed. They can be divided into 6 categories according to their mechanism of action: triple monoaminergic, pure noradrenergic and serotoninergic with multimodal action, opioid, antimuscarinic, and glutamatergic antidepressants. The development is mainly focused on influencing all three monoamines together and newly on glutamatergic transmission. The aim of research is to accelerate the onset of action to only several days and extension of therapeutic indications to patients with pharmacoresistency, suicidality, anxiety, cognitive impairment and alcohol addiction. New antidepressants do not cause excessive sedation, weight gain, QT interval prolongation or sexual dysfunction. Final evalution of their benefits will be possible only after further, especially long-term, studies.

Language: cs

Keywords

suicide; alcoholism; depression; anxiety; review; antidepressant agent; sexual dysfunction; cognitive defect; sedation; opiate; drug mechanism; weight gain; serotoninergic system; Czech Republic; QT prolongation; monoamine; muscarinic receptor blocking agent; noradrenergic system; monoaminergic system; clinical evaluation; Antimuscarinic and glutamatergic compounds; Especially triple antidepressants; Monoaminergic; New antidepressants under development; Non-monoaminergic antidepressants: Opioid